Emerging treatments
Direct oral anticoagulants in select patients with cancer
The US National Comprehensive Cancer Network guidelines suggest consideration of apixaban for venous thromboembolism prophylaxis in patients with gynecologic cancers, and rivaroxaban for patients following laparoscopic surgery for colorectal cancer.[158][167][168] The American Society of Clinical Oncology guidelines suggest that patients undergoing cancer surgery may switch to rivaroxaban or apixaban for extended postoperative thromboprophylaxis after an initial period of low molecular weight heparin or unfractionated heparin.[156][167][168] Evidence for the use of rivaroxaban and apixaban in these settings is limited. An oral regimen may improve adherence in some patients.
Use of this content is subject to our disclaimer